MIRVASO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MIRVASO (MIRVASO).
Selective alpha-2 adrenergic receptor agonist, reducing sympathetic outflow from the CNS, leading to decreased peripheral vascular resistance and reduced intraocular pressure.
| Metabolism | Primarily hepatic via aldehyde dehydrogenase; metabolized to pyruvate and lactate; metabolites are excreted renally. |
| Excretion | Renal 24% unchanged, fecal via bile small fraction |
| Half-life | 28 hours (topical); supports once-daily dosing |
| Protein binding | ~90% bound to plasma proteins |
| Volume of Distribution | 2.6 L/kg, indicating extensive tissue distribution |
| Bioavailability | Low systemic bioavailability after topical application (approx 40% of dose absorbed) |
| Onset of Action | 30 minutes after topical application |
| Duration of Action | Up to 12 hours |
Apply 1 mL topically to the central face (forehead, nose, chin, cheeks) once daily.
| Dosage form | GEL |
| Renal impairment | No dose adjustment required based on GFR. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to limited data. |
| Pediatric use | Not approved for use in pediatric patients below 18 years of age. |
| Geriatric use | No specific dose adjustment; use with caution due to potential increased sensitivity and higher risk of hypotension. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MIRVASO (MIRVASO).
| Breastfeeding | Unknown if excreted in human milk. M/P ratio not determined. Due to potential for serious adverse reactions in nursing infants, decision should be made to discontinue nursing or discontinue drug, taking into account importance of drug to mother. |
| Teratogenic Risk | Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects observed at doses up to 1000 times the MRHD; however, embryotoxicity and fetotoxicity (reduced fetal weight, delayed ossification) occurred at maternally toxic doses. Risk to fetus cannot be ruled out. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to brimonidine or any component of the formulation","Patients receiving MAO inhibitors (risk of hypertensive crisis)","Newborns, infants, and children <2 years of age (risk of CNS depression and apnea)"]
| Precautions | ["May cause hypotension and bradycardia; use caution in patients with cardiovascular disease","Systemic absorption may occur if applied to broken skin or mucous membranes","Avoid use in patients with orthostatic hypotension, severe coronary insufficiency, or cerebrovascular disease","Rebound hypertension upon abrupt discontinuation has been reported (rare with topical use)","Monitor for allergic reactions including contact dermatitis"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and heart rate. Monitor for fetal growth and well-being via ultrasound if used for prolonged periods. No specific fetal monitoring required beyond standard prenatal care. |
| Fertility Effects | No human data on fertility. In animal studies, no adverse effects on fertility or reproductive performance observed at doses up to 200 times the MRHD. |